MRKR Stock Catalyst: Marker Therapeutics Reports Encouraging Response Rates in Phase 1 APOLLO Study

Marker Therapeutics, Inc. announced on 2025-08-26 Marker Therapeutics provided an update on the Phase 1 APOLLO study, highlighting encouraging overall response rates in patients with relapsed lymphoma.

The announcement cited 66%, 50%, 100x10^6 –400x10^6 cells, 12, 9, 15, 100x10^6 –200x10^6 cells, 8, 200x10^6 –400x10^6 cells, 400x10^6 cells, 3–24 months, 5, 3, 78%, 11%, and 12 months.

Marker Therapeutics, Inc. Common Stock has a free float of 13,676,500 shares and 12,938,900 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.